GlucoTrack (NASDAQ:GCTK) (NASDAQ: GCTK) is a medical technology company focused on the development and commercialization of non-invasive glucose monitoring solutions for people living with diabetes. Founded in 2005 and headquartered in Tel Aviv, Israel, the company leverages proprietary ultrasonic, electromagnetic and thermal technologies to measure glucose levels through the earlobe without the need for finger-stick testing. Since its inception, GlucoTrack has aimed to improve the quality of life for insulin-dependent patients by offering a convenient alternative to traditional invasive monitoring methods.
The company’s flagship product, the GlucoTrack® device, is designed to deliver accurate blood glucose readings in under a minute. It features a compact, wearable sensor clip and a portable display unit that records and stores glucose measurements. GlucoTrack continues to invest in research and development, exploring enhancements to its measurement algorithms and user interface to ensure ease of use and clinical reliability. Ongoing studies include efforts to expand the device’s accuracy across a broader range of patient profiles and to integrate data connectivity for remote patient monitoring.
GlucoTrack actively markets its products in Europe, Israel and select markets in Asia, having received CE Mark approval and local regulatory clearances to support commercial launch. The company has forged strategic partnerships with regional distributors and healthcare providers to facilitate product adoption and patient education initiatives. In addition to its core glucose monitoring platform, GlucoTrack is exploring collaborations aimed at combining its non-invasive sensor technology with digital health platforms to enable telemedicine and chronic disease management solutions.
The executive leadership team is led by CEO Michael Roitman, who brings over two decades of experience in medical device commercialization and global market expansion. The board of directors comprises industry veterans with expertise in endocrinology, regulatory affairs and digital health. Under this leadership, GlucoTrack continues to refine its commercialization strategy, pursue additional regulatory approvals and expand its presence in key international markets, with the goal of delivering a user-friendly, non-invasive alternative to traditional glucose monitoring for millions of diabetics worldwide.
